Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1971 1
1979 1
1983 2
1984 4
1985 3
1986 4
1987 2
1988 3
1989 2
1991 1
1993 2
1994 3
1996 1
1997 2
1998 1
2000 1
2001 5
2003 3
2004 2
2005 3
2006 5
2007 3
2008 5
2009 4
2010 6
2011 3
2012 7
2013 2
2014 2
2015 10
2016 4
2017 3
2018 5
2019 4
2020 2
2021 3
2022 5
2023 3
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Tuberculosis.
Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Pai M, et al. Among authors: spigelman m. Nat Rev Dis Primers. 2016 Oct 27;2:16076. doi: 10.1038/nrdp.2016.76. Nat Rev Dis Primers. 2016. PMID: 27784885 Review.
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M; Nix-TB Trial Team. Conradie F, et al. Among authors: spigelman m. N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814. N Engl J Med. 2020. PMID: 32130813 Free PMC article. Clinical Trial.
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M; ZeNix Trial Team. Conradie F, et al. Among authors: spigelman m. N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430. N Engl J Med. 2022. PMID: 36053506 Free PMC article. Clinical Trial.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. Among authors: spigelman m. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Paleomicrobiology of Leprosy.
Spigelman M, Rubini M. Spigelman M, et al. Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.PoH-0009-2015. Microbiol Spectr. 2016. PMID: 27726813 Free article. Review.
Target regimen profiles for tuberculosis treatment.
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Lienhardt C, et al. Among authors: spigelman m. Bull World Health Organ. 2024 Aug 1;102(8):600-607. doi: 10.2471/BLT.24.291881. Epub 2024 May 28. Bull World Health Organ. 2024. PMID: 39070602 Free PMC article.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. Nyang'wa BT, et al. Among authors: spigelman m. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16. Lancet Respir Med. 2024. PMID: 37980911 Free article. Clinical Trial.
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH; SimpliciTB Consortium. Cevik M, et al. Among authors: spigelman m. Lancet Infect Dis. 2024 Sep;24(9):1003-1014. doi: 10.1016/S1473-3099(24)00223-8. Epub 2024 May 17. Lancet Infect Dis. 2024. PMID: 38768617 Free article. Clinical Trial.
Advancing the science in clinical trials for new TB drugs.
Burman W, McNeeley D, Moulton LH, Spigelman M, Vernon A. Burman W, et al. Among authors: spigelman m. Int J Tuberc Lung Dis. 2008 Feb;12(2):111-2. Int J Tuberc Lung Dis. 2008. PMID: 18230241 No abstract available.
Multidrug-resistant tuberculosis.
Spigelman M, Compton C, Gheuens J; Critical Path to TB Drug Regimens. Spigelman M, et al. N Engl J Med. 2012 Nov 29;367(22):2155; author reply 2155-6. doi: 10.1056/NEJMc1210001. N Engl J Med. 2012. PMID: 23190231 No abstract available.
127 results